黑质敏感MRI作为首发精神分裂症治疗抵抗的候选标志物
该研究纳入79例首发精神病患者和20名匹配健康对照,在6个月随访时评估治疗反应,采用黑质内预设体素分析检验NM-MRI信号与治疗反应的关系。非应答者与健康对照的黑质腹侧层NM-MRI信号显著低于应答者,ROC曲线分析显示NM-MRI信号区分非应答者的曲线下面积在0.62至0.85之间。
要点
- 非应答者与健康对照的黑质NM-MRI信号显著低于应答者。
- 黑质腹侧层297个显著体素与治疗反应呈负相关。
- NM-MRI信号区分非应答者的曲线下面积为0.62至0.85。
核心结论
- 研究结果进一步支持药物治疗应答者与非应答者之间存在多巴胺能差异。
- NM-MRI有潜力作为精神分裂症治疗抵抗的临床适用标志物。
研究设计与样本
- 研究纳入79例首发精神病患者和20名匹配健康对照。
- 在6个月随访时评估治疗反应,采用黑质内预设体素分析检验NM-MRI信号与治疗反应的关系。
主要发现
- 黑质腹侧层297个显著体素与治疗反应呈负相关。
- 非应答者和健康对照的NM-MRI信号显著低于应答者。
- ROC曲线分析显示NM-MRI信号区分非应答者的曲线下面积在0.62至0.85之间。
- 患者NM-MRI信号在6个月内未发生变化。
临床怎么用
- NM-MRI信号有望作为无创标志物辅助识别首发精神病中可能治疗抵抗的患者。
- 识别非应答者有助于减少有效治疗的延迟。
局限性
- 研究样本为79例首发精神病患者和20名健康对照,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Markers for treatment resistance in schizophrenia are needed to reduce delays in effective treatment. Nigrostriatal hyperdopaminergic function plays a critical role in the pathology of schizophrenia, yet antipsychotic nonresponders do not show increased dopamine function. Neuromelanin-sensitive MRI (NM-MRI), which indirectly measures dopamine function in the substantia nigra, has potential as a noninvasive marker for nonresponders. Increased NM-MRI signal has been shown in psychosis, but has not yet been assessed in nonresponders. In this study, the authors investigated whether nonresponders show lower NM-MRI signal than responders. METHODS: NM-MRI scans were acquired in 79 patients with first-episode psychosis and 20 matched healthy control subjects. Treatment response was assessed at a 6-month follow-up. An a priori voxel-wise analysis within the substantia nigra tested the relation between NM-MRI signal and treatment response in patients. RESULTS: Fifteen patients were classified as nonresponders and 47 patients as responders. Seventeen patients were excluded, primarily because of medication nonadherence or change in diagnosis. Voxel-wise analysis revealed 297 significant voxels in the ventral tier of the substantia nigra that were negatively associated with treatment response. Nonresponders and healthy control subjects had significantly lower NM-MRI signal than responders. Receiver operating characteristic curve analysis showed that NM-MRI signal separated nonresponders with areas under the curve between 0.62 and 0.85. In addition, NM-MRI signal in patients did not change over 6 months. CONCLUSIONS: These findings provide further evidence for dopaminergic differences between medication responders and nonresponders and support the potential of NM-MRI as a clinically applicable marker for treatment resistance in schizophrenia.
引用
- van der Pluijm M, Wengler K, Reijers PN, et al. Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia. Am J Psychiatry. 2024. PMID: 38476044. doi:10.1176/appi.ajp.20220780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。